Comparative Study Between Rezum and Tamsulosin

NCT07169773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-09-12

No results posted yet for this study

Summary

the investigators aimed to compare the efficacy and safety of Rezūm therapy for the management of benign prostatic hyperplasia (BPH) with Tamsulosin.

Conditions

  • Prostate Hyperplasia

Interventions

DEVICE

Rezum

Rezum procedure in Rezum group

DRUG

Tamsulosin

Tamsulosin were given to Tamsulosin group

Sponsors & Collaborators

  • khaled Abdelsattar Gad Ibrahim

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-05-01
Completion
2023-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07169773 on ClinicalTrials.gov